Express Pharma

DECEMBER 2, 2024

By 2030, half of all US adults are predicted to be obese (New England Journal of Medicine). The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. This alarming trend presents a lucrative opportunity for drugmakers. However, the emergence of oral therapies is reshaping the landscape.

Labelling 126

Labelling Diabetes Drug Development 126

European Pharmaceutical Review

SEPTEMBER 21, 2023

billion by 2030. In this Q&A, Karen Pinachyan, Head of Medical Affairs Europe at CSL Behring summarises key considerations for gene therapy drug development and the ideal approach for alleviating economic strain when advancing these modern treatments. How has the gene therapy landscape evolved over the last several years?

Drug Development 96

Drug Development Pharmaceutical Companies Pharmaceutical Companies Diabetes 96

PharmaShots

APRIL 3, 2023

old, for use by women with diabetes who are pregnant & for wear time of up to 15 days. of revenue in 2023 from its four in-line therapies & bringing Pfizer $10B+ in risk-adjusted revenues by 2030. The results also showed a reduction in risk of hospitalization for any cause with 14% relative risk reduction (24.8

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40